Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761108 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 387
- Enrollment target
- 20
- Study locations
NCT03761108: Recruiting Phase 1 study of Multiple Myeloma, sponsored by Regeneron Pharmaceuticals.
NCT03761108 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 387 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03761108, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 387 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving linvoseltamab * How linvoseltamab works in the body * How much linvoseltamab is present in the blood * How linvoseltamab may work to treat cancer
Primary Outcome
Phase 1 and Phase 2 for Japanese cohort only
Conditions Studied
Interventions
- DRUG Linvoseltamab
Study Locations (20)
Other
- ZNA Psychiatrisch Ziekenhuis Stuivenberg - Antwerp
- Cliniques Universitaires Saint-Luc - Brussels
- Universitatsklinikum Wurzburg - Würzburg
Florida
- Sylvester Comprehensive Cancer Center - Miami
- Moffitt Cancer Center - McKinley Drive - Tampa
Michigan
- C. S. Mott_University of Michigan - Ann Arbor
- Barbara Ann Karmanos Cancer Center - Detroit
New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center - New York
Georgia
- Emory University Hospital - Atlanta
Indiana
- Indiana University_Michigan Street - Indianapolis
Kentucky
- Norton Cancer Institute - Louisville
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2033-06-16 |
| Phase | Phase 1 |
What NCT03761108 shows while recruiting
NCT03761108 is an interventional study that assigns participants to a tested intervention. The registered 387 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Linvoseltamab is the first listed.
NCT03761108 names 20 study sites across 15 states, led by Other, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT03761108 about?
NCT03761108 is a clinical study titled "Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma". The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que...
What is the current status of trial NCT03761108?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 387 participants. The study started on 2019-01-23. Estimated completion is 2033-06-16.
What conditions does trial NCT03761108 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03761108?
The interventions under investigation include: Linvoseltamab (DRUG).
Who is sponsoring clinical trial NCT03761108?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03761108 being conducted?
This trial has 20 study locations across Florida, Georgia, Indiana, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03761108's enrollment target sits among peer trials
387 60th of 438 higher than 379 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05572632 · 387 participants · NA
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
- NCT06917079 · 387 participants · Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
- NCT05157880 · 388 participants · NA
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI